The field of pharmaceutical environmental life cycle data is moving fast. In recent months, significant progress has been made on one of its most persistent challenges: data gaps. These gaps affect critical applications such as life cycle assessment (LCA), product carbon footprint (PCF), and Scope 3 emissions accounting.

Pharmaceutical companies have long struggled to find emissions data for the thousands of specialized chemical substances in their supply chains. A common workaround has been to fill these gaps with data from heterogeneous sources that follow different methodological standards. This, however, introduces inconsistencies that can undermine the comparability and defensibility of results.

New approaches based on retrosynthesis, AI, or a combination of both promise to improve data availability for substances that were previously out of reach. But they also raise new questions about data quality, methodological consistency, and the extent to which analyses can be updated over time. These questions matter if such approaches are to be used reliably in industry reporting.

In this webinar, Carbon Minds is joined by Dr. Sebastian Fischer from Bayer to share first-hand insights into the challenges of emissions accounting in the pharmaceutical industry, discuss current approaches and their limitations, and look at how recent technical advances are shaping the path forward. We will also introduce the Carbon Minds approach to using these new technical possibilities without compromising data quality, updatability, methodological consistency, or third-party certification.

Join us to explore these advances and learn how your organization can benefit from improved data coverage while maintaining the rigor and reliability that environmental life cycle assessment and carbon accounting demand.